Across TCGA pan-cancer cohorts, ZNF548 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF548 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ZNF548 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF548 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, LUSC, and PRAD are the cancer types where ZNF548 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.141	0.904	<.001	36	view →
LUSC	OS	Median	III,IV	0.140	0.664	.016	12	view →
PRAD	DFS	Median	All	0.617	0.886	.013	6	view →
UCEC	OS	Median	All	0.974	0.864	.040	4	view →
ESCA	OS	Median	II,III,IV	0.345	0.686	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF548 tumor-vs-normal RNA expression · all ZNF548 data types